T he US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to a cancer drug called dostarlimab ...

GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli ...

In the world of health news, some significant breakthroughs and setbacks have emerged. GSK announced partial success in its ...

Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...

Hugely promising cancer drug dostarlimab is one step closer to being widely available, after the Food and Drug Administration ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...

GSK plc（伦敦证券交易所/纽约证券交易所代码：GSK），一家市值673.5亿美元、目前交易价格接近52周低点的知名制药公司，今天公布了其FIRST三期临床试验的积极结果。该试验评估了Zejula（尼拉帕利）和Jemperli（dostarlimab）在治疗晚期卵巢癌方面的效果。

Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...

LONDON, UK I, 2024 I GSK plc (LSE/NYSE: GSK) today announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...